Home / Market News / $CLBT

$CLBT news and market catalysts

The 11 most recent market catalysts affecting $CLBT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

11 catalysts 3 high impact 3 bullish 5 bearish Software & Services
Nov 12, 2026 Corporate Catalyst Bullish Impact 85
Cellebrite Reports Third-Quarter 2026 Financial Results
Cellebrite announced better-than-expected Q3 2026 financial results, with revenue and adjusted EPS surpassing FactSet consensus estimates. This strong performance led the company t…
Nov 6, 2026 Corporate Catalyst Neutral Impact 60
Cellebrite Appoints Former Okta Executive Rogerio Rizzi as EVP of Corporate Strategy and Development
Cellebrite announced the appointment of Rogerio Rizzi, a former Okta executive, as its Executive Vice President of Corporate Strategy and Development. This matters because Rizzi ha…
Nov 5, 2026 Corporate Catalyst Neutral Impact 55
Cellebrite Appoints Rogerio Rizzi as Executive Vice President of Corporate Strategy and Development
Cellebrite has appointed Rogerio Rizzi as EVP of Corporate Strategy and Development, a key leadership role. This matters because Rizzi's background in establishing corporate strate…
Aug 14, 2026 Corporate Catalyst Bearish Impact 55
JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $16
JP Morgan's decision to lower Cellebrite DI's price target from $20 to $16, while keeping an 'Overweight' rating, signals a recalibration of the analyst's valuation model. This cou…
Aug 13, 2026 Market Technicals Bullish Impact 55
12 Information Technology Stocks Moving In Thursday's Intraday Session
This 8-K filing, generated by Benzinga's automated content engine, serves as a snapshot of intraday trading activity for a selection of information technology stocks. It highlights…
Aug 13, 2026 Corporate Catalyst Bearish Impact 95
Cellebrite Shares Plunge Thursday: What's Driving the Move?
Cellebrite DI Ltd. experienced a significant stock price drop after announcing Q2 financial results that fell short of revenue expectations and revising down its full-year 2026 rev…
Aug 13, 2026 Corporate Catalyst Bearish Impact 95
Cellebrite DI shares are trading lower after the company reported worse-than-expected Q2 sales results and issued Q3 sales guidance below estimates. Also, the company cut its FY26 sales guidance below estimates.
This headline represents a major corporate catalyst for Cellebrite DI (CLBT). The combination of a Q2 sales miss, lower-than-expected Q3 guidance, and a significant cut to long-ter…
Aug 13, 2026 Corporate Catalyst Bearish Impact 75
Cellebrite DI Lowers FY2026 Sales Guidance from $565.000M-$571.000M to $555.000M-$561.000M vs $568.048M Est
Cellebrite DI (CLBT) has announced a reduction in its sales guidance for fiscal year 2026, moving from an initial range of $565.000M-$571.000M to a new range of $555.000M-$561.000M…
Aug 13, 2026 Corporate Catalyst Neutral Impact 75
Cellebrite DI Sees Q3 Sales $145.000M-$148.000M vs $150.298M Est
Cellebrite DI (CLBT) announced Q3 sales guidance of $145 million to $148 million, which is notably lower than the analyst consensus estimate of $150.298 million. This downward revi…
Aug 13, 2026 Corporate Catalyst Bearish Impact 65
Cellebrite DI Q2 Adj. EPS $0.11, Inline, Sales $131.138M Miss $131.874M Estimate
Cellebrite DI (CLBT) announced its Q2 earnings, reporting an adjusted EPS of $0.11, which aligned with analyst consensus. However, the company's sales of $131.138 million missed th…
Aug 6, 2026 Corporate Catalyst Bullish Impact 55
DA Davidson Maintains Buy on Cellebrite DI, Raises Price Target to $22
DA Davidson analyst Rudy Kessinger has maintained a 'Buy' rating on Cellebrite DI (CLBT) and raised the price target from $20 to $22. This action signals a positive outlook from a …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.